PandemieGrippaleV1, Main, Merge, bibRecord, 001779

The history of MF59® adjuvant: a phoenix that arose from the ashes

Identifieur interne : 001779 ( Main/Merge ); précédent : 001778; suivant : 001780

The history of MF59® adjuvant: a phoenix that arose from the ashes

Auteurs : Derek T. O'Hagan [États-Unis] ; Gary S. Ott [États-Unis] ; Gary Van Nest [États-Unis] ; Rino Rappuoli [Italie] ; Giuseppe Del Giudice [Italie]

Source :

Expert review of vaccines [ 1476-0584 ] ; 2013.

RBID : Pascal:13-0153100

Descripteurs français

Pascal (Inist)
- Grippe, Immunoprophylaxie, Historique, Vaccin, Prévention, Adjuvant immunologique, Pandémie, Adjuvant MF59.
Wicri :
- topic : Historique, Vaccin.

English descriptors

KwdEn :
- Case history, Immunological adjuvant, Immunoprophylaxis, Influenza, Prevention, Vaccine.

Abstract

The first clinical trial of an MF59®-adjuvanted influenza vaccine (Novartis) was conducted 20 years ago in 1992. The product that emerged (Fluad®, Novartis) was licensed first in Italy in 1997 and is now licensed worldwide in 30 countries. US licensure is expected in the coming years. By contrast, many alternative adjuvanted vaccines have failed to progress. The key decisions that allowed MF59 to succeed in such a challenging environment are highlighted here and the lessons that were learned along the way are discussed. MF59 was connected to vaccines that did not succeed and was perceived as a 'failure' before it was a success. Importantly, it never failed for safety reasons and was always well tolerated. Even when safety issues have emerged for alternative adjuvants, careful analysis of the substantial safety database for MF59 have shown that there are no significant concerns with widespread use, even in more 'sensitive' populations.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000311
to stream PascalFrancis, to step Curation: 001B15
to stream PascalFrancis, to step Checkpoint: 000182

Links to Exploration step

Pascal:13-0153100

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The history of MF59® adjuvant: a phoenix that arose from the ashes</title>
<author><name sortKey="O Hagan, Derek T" sort="O Hagan, Derek T" uniqKey="O Hagan D" first="Derek T." last="O'Hagan">Derek T. O'Hagan</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novartis Vaccines and Diagnostics, 350 Massachusetts Avenue</s1>
<s2>Cambridge, MA 02139</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ott, Gary S" sort="Ott, Gary S" uniqKey="Ott G" first="Gary S." last="Ott">Gary S. Ott</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Dynavax Technologies Corp., 2929 Seventh Street</s1>
<s2>Berkeley, CA 94710</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Nest, Gary" sort="Van Nest, Gary" uniqKey="Van Nest G" first="Gary" last="Van Nest">Gary Van Nest</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Medlmmune LLC, 319 N. Bernado Avenue</s1>
<s2>Mountain View, CA 94043</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rappuoli, Rino" sort="Rappuoli, Rino" uniqKey="Rappuoli R" first="Rino" last="Rappuoli">Rino Rappuoli</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1</s1>
<s2>53100 Siena</s2>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>53100 Siena</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Del Giudice, Giuseppe" sort="Del Giudice, Giuseppe" uniqKey="Del Giudice G" first="Giuseppe" last="Del Giudice">Giuseppe Del Giudice</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1</s1>
<s2>53100 Siena</s2>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>53100 Siena</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0153100</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0153100 INIST</idno>
<idno type="RBID">Pascal:13-0153100</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000311</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001B15</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000182</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000182</idno>
<idno type="wicri:doubleKey">1476-0584:2013:O Hagan D:the:history:of</idno>
<idno type="wicri:Area/Main/Merge">001779</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The history of MF59® adjuvant: a phoenix that arose from the ashes</title>
<author><name sortKey="O Hagan, Derek T" sort="O Hagan, Derek T" uniqKey="O Hagan D" first="Derek T." last="O'Hagan">Derek T. O'Hagan</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Novartis Vaccines and Diagnostics, 350 Massachusetts Avenue</s1>
<s2>Cambridge, MA 02139</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ott, Gary S" sort="Ott, Gary S" uniqKey="Ott G" first="Gary S." last="Ott">Gary S. Ott</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Dynavax Technologies Corp., 2929 Seventh Street</s1>
<s2>Berkeley, CA 94710</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Nest, Gary" sort="Van Nest, Gary" uniqKey="Van Nest G" first="Gary" last="Van Nest">Gary Van Nest</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Medlmmune LLC, 319 N. Bernado Avenue</s1>
<s2>Mountain View, CA 94043</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rappuoli, Rino" sort="Rappuoli, Rino" uniqKey="Rappuoli R" first="Rino" last="Rappuoli">Rino Rappuoli</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1</s1>
<s2>53100 Siena</s2>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>53100 Siena</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Del Giudice, Giuseppe" sort="Del Giudice, Giuseppe" uniqKey="Del Giudice G" first="Giuseppe" last="Del Giudice">Giuseppe Del Giudice</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1</s1>
<s2>53100 Siena</s2>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>53100 Siena</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Expert review of vaccines</title>
<idno type="ISSN">1476-0584</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Expert review of vaccines</title>
<idno type="ISSN">1476-0584</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Case history</term>
<term>Immunological adjuvant</term>
<term>Immunoprophylaxis</term>
<term>Influenza</term>
<term>Prevention</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Grippe</term>
<term>Immunoprophylaxie</term>
<term>Historique</term>
<term>Vaccin</term>
<term>Prévention</term>
<term>Adjuvant immunologique</term>
<term>Pandémie</term>
<term>Adjuvant MF59</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Historique</term>
<term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The first clinical trial of an MF59®-adjuvanted influenza vaccine (Novartis) was conducted 20 years ago in 1992. The product that emerged (Fluad®, Novartis) was licensed first in Italy in 1997 and is now licensed worldwide in 30 countries. US licensure is expected in the coming years. By contrast, many alternative adjuvanted vaccines have failed to progress. The key decisions that allowed MF59 to succeed in such a challenging environment are highlighted here and the lessons that were learned along the way are discussed. MF59 was connected to vaccines that did not succeed and was perceived as a 'failure' before it was a success. Importantly, it never failed for safety reasons and was always well tolerated. Even when safety issues have emerged for alternative adjuvants, careful analysis of the substantial safety database for MF59 have shown that there are no significant concerns with widespread use, even in more 'sensitive' populations.</div>
</front>
</TEI>
<affiliations><list><country><li>Italie</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Massachusetts</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="O Hagan, Derek T" sort="O Hagan, Derek T" uniqKey="O Hagan D" first="Derek T." last="O'Hagan">Derek T. O'Hagan</name>
</region>
<name sortKey="Ott, Gary S" sort="Ott, Gary S" uniqKey="Ott G" first="Gary S." last="Ott">Gary S. Ott</name>
<name sortKey="Van Nest, Gary" sort="Van Nest, Gary" uniqKey="Van Nest G" first="Gary" last="Van Nest">Gary Van Nest</name>
</country>
<country name="Italie"><noRegion><name sortKey="Rappuoli, Rino" sort="Rappuoli, Rino" uniqKey="Rappuoli R" first="Rino" last="Rappuoli">Rino Rappuoli</name>
</noRegion>
<name sortKey="Del Giudice, Giuseppe" sort="Del Giudice, Giuseppe" uniqKey="Del Giudice G" first="Giuseppe" last="Del Giudice">Giuseppe Del Giudice</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001779 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001779 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:13-0153100
   |texte=   The history of MF59® adjuvant: a phoenix that arose from the ashes
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

The history of MF59® adjuvant: a phoenix that arose from the ashes

The history of MF59® adjuvant: a phoenix that arose from the ashes

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri